NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $9.73 +0.12 (+1.25%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Niagen Bioscience Stock (NASDAQ:NAGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$9.66▼$10.5750-Day Range$9.04▼$14.4152-Week Range$2.69▼$14.69Volume1.84 million shsAverage Volume1.29 million shsMarket Capitalization$775.97 millionP/E Ratio46.34Dividend YieldN/APrice Target$13.22Consensus RatingBuy Company Overview Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. Read More Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 29% of companies evaluated by MarketBeat, and ranked 791st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNiagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 73.92, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 73.92, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.97.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 12.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NAGE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NAGE. News and Social Media2.5 / 5News Sentiment0.48 News SentimentNiagen Bioscience has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Niagen Bioscience this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows13 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.39% of the stock of Niagen Bioscience is held by insiders.Percentage Held by InstitutionsOnly 15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address NAGE Stock News HeadlinesEarnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsAugust 8 at 11:14 AM | finance.yahoo.comNiagen Bioscience Reports Strong Q2 Sales GrowthAugust 6 at 12:41 AM | msn.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.August 8 at 2:00 AM | Priority Gold (Ad)Niagen Bioscience Inc (NAGE) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 6 at 7:40 PM | finance.yahoo.comNiagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year ...August 6 at 5:13 PM | gurufocus.comNiagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year OutlookAugust 6 at 4:02 PM | businesswire.comExamining the Future: Niagen Bioscience's Earnings OutlookAugust 5 at 6:33 PM | benzinga.comNiagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth ConferenceAugust 4, 2025 | finance.yahoo.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $5.48 at the start of the year. Since then, NAGE shares have increased by 77.6% and is now trading at $9.73. How were Niagen Bioscience's earnings last quarter? Niagen Bioscience, Inc. (NASDAQ:NAGE) released its quarterly earnings results on Wednesday, August, 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. The company had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a trailing twelve-month return on equity of 23.12%. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 WebN/A Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Price Target for Niagen Bioscience$13.22 High Price Target$23.00 Low Price Target$8.00 Potential Upside/Downside+35.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.17 Trailing P/E Ratio46.34 Forward P/E RatioN/A P/E GrowthN/ANet Income$8.55 million Net Margins15.24% Pretax Margin15.76% Return on Equity23.12% Return on Assets15.53% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.12 Sales & Book Value Annual Sales$99.60 million Price / Sales7.79 Cash Flow$0.06 per share Price / Cash Flow162.47 Book Value$0.80 per share Price / Book12.16Miscellaneous Outstanding Shares79,750,000Free Float71,373,000Market Cap$775.97 million OptionableN/A Beta2.12 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NAGE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.